Measurement in Blood of a Circulating NET mRNA Gene to Predict Surgical Efficacy

#1878

Introduction: Surgery is the only curative treatment for GEP-NETs, but identifying post-surgery residual disease is difficult and often delayed.

Aim(s): Examine whether a blood multianalyte neuroendocrine gene transcript assay defines the completeness of surgical resection and identifies residual disease.

Materials and methods: GEP-NETs (n=48) were evaluated. Group I (retrospective: n=33); Group II (prospective: n=15). Blood samples were obtained before and 1 month after surgery. Disease status was evaluated at 6 months (CT/MRI;68Ga DOTA- PET/CT, 99mTc TOC SPECT/CT). CgA levels were the comparator.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kidd M

Authors: Modlin I, Frilling A, Salem R, Cichocki A, Ćwikła J,

Keywords: NETest, surgery, biomarker, NET,